PRP Blocks Tumor Growth and Aggressive Dissemination

A Long-Term Therapy Based on a Pancreatic Proenzyme Formulation

We are developing a long-term therapy based on a pancreatic proenzyme formulation to prevent tumor recurrence and metastasis, the main cause of patient death from cancer. Our lead product, PRP, is a novel, patented, formulation consisting of two proenzymes mixed in a synergetic ratio that targets solid tumors. The Company’s initial target patient populations include pancreatic, ovarian and colorectal cancers.

Drug Pipeline
Research Screening Preclinical Phase IIa Phase IIb Phase III
PRP
Research Phase complete
Screening Phase complete
Preclinical Phase in progress
Phase IIa Phase not started
Phase IIb Phase not started
Phase III Phase not started
  • Bioanalytical assay method development for quantification of PRP in animal and human serum and plasma samples
  • GMP production of PRP for patient trials.
Play Video

A New Frontier In Cancer Therapy

Watch how Propanc is pioneering a new approach to cancer therapy

How PRP Works

PRP’s anti-cancer effects blocks tumor growth and aggressive dissemination by:

<p>Controlling cancer cell migration</p>

Controlling cancer cell migration

<p>Increasing the expression of the protein responsible for cell-to-cell contact</p>

Increasing the expression of the protein responsible for cell-to-cell contact

<p>Inhibiting tumor blood vessel formation</p>

Inhibiting tumor blood vessel formation

<p>Strongly suppressing cell invasion and metastasis</p>

Strongly suppressing cell invasion and metastasis

<p>Triggering cell death</p>

Triggering cell death

<p>Enhancing the body’s own immune system</p>

Enhancing the body’s own immune system

Several uses for PRP in clinical situations

Early stage management of solid tumors

Long term therapy following standard treatment

Preventative measure for genetically screened at risk patients

What We Have Achieved

After extensive laboratory research and a limited amount of human testing, we have evidence that PRP:

  • Reduces cancer cell growth via promotion of cell differentiation
  • Enhances cell adhesion and may suppress metastasis progression
  • Has no serious side effects and improves patient survival

The History of PRP

PRP is based on the original work undertaken by John Beard, a professor of embryology at Edinburgh University nearly 100 years ago, using fresh pancreatic enzyme extracts.

Through advancements in science and technology, we have discovered an opportunity to commercialize an improved version of PRP administered once daily in an outpatient setting. Our intention is to supply this treatment to markets worldwide.

Our Technology: A Unique Mode of Action

When Epithelial-Mesenchymal Transition (EMT) is activated, it causes epithelial cancer cells to become invasive and stem cell-like. PRP has the ability to reverse the conversion from an epithelial to a mesenchymal phenotype, reducing the metastatic potential of the tumor.

How Our Technology Works

Significant Market Opportunity for Cancer Treatment

According to the World Health Organization, cancer deaths are expected to increase:

View Market Need
More Than 10M People by 2020
More Than 13M People by 2030